Coding Bio
Founded 2021 · 23 employees on LinkedIn · 5 known investors
Coding Bio develops modular immunotherapies for cancer patients, using a high-throughput lab to screen millions of protein candidates in living cells and a machine learning platform to design and optimize therapies for immune activation. The company operates in the immuno-oncology and cell therapy space, aiming to accelerate development of CAR and related therapies.
Also known as Coding Bio · coding.bio
Founders & leadership
Coding Bio was founded in 2021 by Simon Bornschein and Yulia Lampi.
Investors · 5
Company profile
researched Aug 2026Coding Bio is an Oxford, United Kingdom-based company that develops modular protein immunotherapies for cancer patients. Its stated approach combines a high-throughput laboratory with a machine learning platform: the lab generates and tests large libraries of modular proteins directly in living cells to identify designs that best induce an immune response, and the resulting screening data is used by an ML platform that analyses protein structures to find patterns affecting therapy quality and iterates across designs to maximise performance.
The company frames its work against what it describes as current trade-offs in immunotherapy development between speed, cost and quality, noting that development is typically conducted at low throughput and high expense and that most developers focus on protein binding rather than immune response. Coding Bio positions its combined screening and engineering approach as producing candidate therapies on a timescale of months, with partners then advancing them toward the clinic. The company describes itself as merging biology and computer science to build a model of the immune system, and connecting data across different disease states to inform decisions across projects.
Founding story
Co-founder and CEO Simon Bornschein holds a PhD in immuno-oncology with experience in cell therapy and CAR therapy development, previously at Celyad and Quell Therapeutics. Co-founder and CSO Yulia Lampi holds a PhD in molecular and cell biology; her earlier work at Aelin Therapeutics and Quell Therapeutics is cited as the inspiration for co-founding Coding Bio. CTO Nils Hammerla holds a PhD in computer science with 15 years applying machine learning, having led ML research teams at Twitter and Babylon Health [0].
Business model
The website refers to partners moving therapies faster to the clinic and invites organisations to "build with" the company, indicating a partnering orientation for its screening and design platform [0].
▸Full profile — market position, technology, go-to-market, geography
Market position
Positions itself as building best-in-class modular immunotherapies with faster engineering cycles than conventional low-throughput development approaches, and as optimising for immune activation rather than protein binding alone [0].
Screening millions of candidates in living cells to measure immune activation, generating datasets used to train a generative ML design platform; stated ability to build therapies in months [0].
Technology
Two linked components are described: a high-throughput lab that screens millions of modular protein candidates directly in cells, measuring induction of an immune response rather than binding alone; and a machine learning platform using generative modelling that analyses protein structures to identify features affecting therapy quality and iterates over designs. Data generated by screening at scale feeds the ML platform, and data from different disease states is pooled to improve understanding of the immune system across projects [0].
Go-to-market
Direct partnering and enquiry via the company website, alongside recruitment of computational and scientific staff at all career stages [0].
Cancer patients are the stated ultimate beneficiaries; the company addresses immunotherapy developers and partners who take candidate therapies into clinical development [0].
Geography
Based in Oxford, United Kingdom (postcode OX3 0BP) [0].
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
▸Research sources · 1
primary sources listed
- coding.bio Websitecoding.bio · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Coding Bio do?
- Oxford-based Coding Bio engineers modular protein immunotherapies for cancer using high-throughput cell screening and ML.
- Who founded Coding Bio?
- Coding Bio was founded by Simon Bornschein, Yulia Lampi in 2021.
- Who are Coding Bio's investors?
- Coding Bio's investors include 2048 Ventures, Metaplanet, Samos Investments, The Venture Collective, BoxOne Ventures.